Please enable JavaScript.
Coggle requires JavaScript to display documents.
FDA – Pharmaceutical Industry Relationship - Coggle Diagram
FDA – Pharmaceutical Industry Relationship
Research Question (Left Side)
Is the relationship between FDA and the pharmaceutical industry a good one?
Key evaluation
Strengths → innovation, trust, cooperation
Weaknesses → conflicts of interest, bias, profit motives
Conclusion → necessary but uneasy partnership
FDA (Food and Drug Administration)
Role & Authority
U.S. federal regulatory body under HHS
Protects public health
Functions
Approves drugs, devices, vaccines, biologics
Ensures safety, efficacy, and quality
Post-marketing surveillance
Issues recalls if unsafe
Strengths
Provides global credibility
Safeguards public trust
Strict evidence requirements
Weaknesses
Dependent on industry-submitted data
Limited resources vs. vast pharma market
Accused of slow approvals
Sometimes too lenient under pressure
Comparison
Other regulators: India’s CDSCO, Europe’s EMA
FDA = stricter, global credibility
CDSCO = faster, cheaper, but rigor questioned
Pharmaceutical Industry
Functions
Research & development
Manufacturing
Marketing & distribution
Goals
Innovation & profit
Market expansion
Strategies
Heavy R&D investments
Lobbying & political influence
Direct-to-consumer advertising
Criticisms
High drug prices & affordability concerns
Aggressive patenting to block generics
Over-marketing (e.g., opioids crisis)
Prioritizing profits over patients
Positive / Cooperative Aspects
FDA approval provides legitimacy
Supports drug innovation
Guidance for trial design
Regulatory clarity encourages R&D
Fast-tracking in emergencies
Emergency Use Authorizations (EUAs)
COVID-19 vaccines (Pfizer, Moderna)
India → Covaxin, Covishield (CDSCO)
Collaboration on clinical trials
Shared data frameworks
International harmonization (ICH guidelines)
Benefits
Public trust
Access to life-saving drugs faster
Encourages global investment
Negative / Critical Aspects
Revolving door (conflict of interest)
FDA officials joining pharma companies
Industry lobbying influence
Slow approval process
Lengthy review timelines
Patients wait for life-saving drugs
Too lenient under industry pressure
Approval of drugs with limited evidence
Safety concerns overlooked
Example → OxyContin & opioid epidemic
Dependence on pharma user fees
Prescription Drug User Fee Act (PDUFA)
Creates perception of bias
Public perception
Pharma = profit-driven
FDA = sometimes inconsistent